Carol Patterson was waiting for a call from her doctor. When the phone rang on that afternoon in August 2011 at her home in Cortland, Ohio, it wasn’t a physician on the other end. A woman named Robin said she was representing the American Diabetes Association.
A bionic pancreas designed to take over blood sugar control in people with type 1 diabetes got patients to near normal levels and prevented dangerous drops better than standard therapy in two demanding five-day trials.
Novo Nordisk A/S’s combination of a new insulin with its established Victoza therapy lowered blood- sugar to unprecedented levels and should be an important diabetes treatment once approved, Chief Science Officer Mads Krogsgaard Thomsen said.
Diet and exercise remain the best bet for staving off diabetes in patients at risk for the disease, according to a 15-year follow up on a landmark study that set lifestyle intervention as an effective approach.
Merck & Co., Novo Nordisk A/S and other makers of popular treatments for diabetes may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.
Sanofi’s experimental insulin Toujeo controlled diabetes better than the company’s best-selling Lantus in three tests that suggest the new drug may help buoy sales when the older one loses patent protection.